<DOC>
	<DOC>NCT02997605</DOC>
	<brief_summary>The purpose of this study is to compare the proportion of patients who could withdraw from prednisone and hydrocortisone one year after a progressive decrease of GC (GC tapering) or a hydrocortisone replacement therapy in rheumatoid arthritis in remission or low disease activity.</brief_summary>
	<brief_title>Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>French multicenter double-blind controlled parallel-group randomized clinical trial Phase IV assessing whether a hydrocortisone replacement therapy could increase the success rate of GC withdrawal at one year, in patients with Rheumatoid Arthritis in low disease activity or remission, in comparison to progressive decrease of GC (GC tapering).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients ≥ 18 years old. Fulfilling the 2010 American College of Rheumatology (ACR)/EULAR criteria for RA. Treated with a stable dose of Synthetic Disease Modifying AntiRheumatic Drugs (sDMARD) or Biological Disease Modifying AntiRheumatic Drug (bDMARD) for at least 3 months. Who have been treated with prednisone or prednisolone for at least 6 months. With a stable dose of prednisone or prednisolone of 5mg/day for at least 3 months. With a DAS28 ≤3.2 for at least 3 months. Patients with health insurance Patients who have signed a written informed consent form. Any chronic condition that would need long term corticoid use (e.g. chronic lung diseases). Evidence of a flare within the last 3 months. Evidence of an allergy or intolerance to hydrocortisone or prednisone. Chronic idiopathic, or autoimmune clinical adrenal insufficiency. GC joint injections within the last 3 months or scheduled in the next 3 months. Any disease with GC contraindication. Association with sultopride and with live vaccines Significant trauma or major surgery within the 3 months prior to the baseline visit. Scheduled surgery in the next 12 months. Fibromyalgia. Foreseeable poor compliance with the strategy. Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation. Alcohol and/or drug misuse as determined by the investigator. Pregnancy or breastfeeding. Patient is not willing to sign the informed consent. Juridical Protection DAS28&gt;3.2 after one month of a stable dose of prednisone 5 mg/day.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>low disease activity</keyword>
	<keyword>remission</keyword>
</DOC>